- ends -
|Full size images available for download at http://bit.ly/1TmCMPO|
Notes for editors
About the trial
This was an investigator-initiated double-blind, randomized, placebo-controlled, parallel-group trial from a single centre, involving a total of 193 women planning pregnancy (20-40 years old) with 25OHD level below 50 nmol/L.
Daily supplementation of cholecalciferol 70 mcg (2800 IU) (70-VitD3), 35 mcg (1400 IU) (35-VitD3) or matching placebo was administered before conceiving and continued until 16 weeks post partum. 25OHD, birth weight, fertility, and complication were evaluated.
Baseline level of 25OHD did not differ between groups (mean 43 nmol/L; p=0.91). Levels of 25OHD increased dose-dependently in response to treatment (p < 0.001).
A total of 108 women (56%) conceived within 12 months after randomization, 41 (38%) in the placebo group, 31 (29%) in the 70-VitD3, and 36 (33%) in the 35-VitD3 group. Compared with placebo, the 35-VitD3 group did not affect pregnancy chances significantly (HR: 0.79; 95% CI: 0.48, 1.28), but chances of conceiving were significantly reduced by a daily supplement of 70 mcg (HR: 0.52; 95% CI: 0.31, 0.87). Birth weight did not differ significantly between the vitamin D3 treated and the placebo group. Complications during labour were significantly more frequent in the placebo- compared with the combined vitamin D3 group (52% vs. 23%, p < 0.005), although specific complications did not differ between groups. There were no differences between groups on any safety measures.
The trial concluded that high doses of vitamin D3 (70 mcg/daily) may reduce the likelihood of conceiving but may also be associated with fewer complications during childbirth without affecting birth weight.
Approved by The Ethical Committee of Denmark (M-20090097).
About ECTS 2016
ECTS 2016 is the 43rd annual congress of the European Calcified Tissue Society (ECTS), held in Rome, Italy on May 14-17, 2016, in collaboration with the Cancer and Bone Society.
ECTS 2016 gives delegates the opportunity to collaborate with leading international researchers and clinical colleagues. Main discussion points are the latest in high quality science and research to benefit clinical practice.
ECTS 2017, the 44th congress, will be held in Salzberg, Austria, May 13-16, 2017.
See http://ects2017.org .
About The European Calcified Tissue Society
The European Calcified Tissue Society (ECTS) is the major organisation in Europe for researchers and clinicians working in the field of calcified tissues and related fields. ECTS acts as a forum for the dissemination of high quality research through its annual meeting, the European Symposium on Calcified Tissues, and through training courses and workshops.
Calcified tissues are central to a healthy skeleton and to bone disorders - such as osteoporosis, back pain and fractures - that make life a misery for countless people. Children can inherit some forms of bone diseases causing bone pain, shortness and deformed limbs.
For further information, please contact:
Roberta Mugnai, ECTS executive director
European Calcified Tissue Society (ECTS)
Tel: + 32 476 520 716
ECTS 2016: http://2016.ectscongress.org/
Event hashtag: https://twitter.com/hashtag/ECTS2016
Published for European Calcified Tissue Society (ECTS) by Press Dispensary